GlassScriptPhysician profile
Brett P Thomas
NPI 1215025457
$1,061.98
in general payments reported to CMS, 2019-2025
9 companies · $49.26 in 2025
The $49.26 reported for 2025 was less than what a typical Neuromusculoskeletal Medicine & Omm provider received nationally (typical 2025 total: $119).
See the full distribution for Neuromusculoskeletal Medicine & OMM
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $69.62 · 2022: $254 · 2023: $143 · 2024: $546 · 2025: $49.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $739.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $738.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $337.57 | 2022-2024 | Ubrelvy, Qulipta, Skyrizi |
| Janssen Biotech, INC. | $204.92 | 2021-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $162.69 | 2022-2024 | Dupixent |
| Ucb, INC. | $126.38 | 2024-2025 | Bimzelx |
| Janssen Scientific Affairs, LLC | $109.51 | 2024 | Tremfya |
| Amgen INC. | $48.05 | 2021 | |
| Depuy Synthes Sales INC. | $29.19 | 2024 | Orthovisc, Monovisc |
| Novartis Pharmaceuticals Corporation | $24.97 | 2024 | |
| Almirall LLC | $18.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.